jurgenfr Dynavax ( NASDAQ: DVAX ) is down ~6% in after-hours trading Wednesday after posting Q1 2024 results that missed on both lines . The company also reaffirmed its earlier 2024 guidance. It sees product revenue of its hepatitis b vaccine HEPLISAV-B -- its only marketed product -- of $265M-$280M.
Consensus for overall revenue is $287.96M. In the quarter, Dynavax ( DVAX ) saw its net loss narrow ~64 % year over year to ~$8.
7M. Net loss per share, basic and diluted, went to -$0.07 from -$0.
19. At the end of the quarter (March 31), the company reported cash, cash equivalents, and marketable securities of $723.5M compared to $742.
3M on Dec. 31, 2023. However, Dynavax said it expects to have more of this figure on Dec.
31, 2024 than at the end of 2023. More on Dynavax Dynavax Technologies: Still A Believer Dynavax: Holding Firm Despite Its Missing Cash Cow Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript Dynavax GAAP EPS of -$0.07 misses by $0.
04, revenue of $50.79M misses by $4.19M Dynavax GAAP EPS of $0.
00 beats by $0.01, revenue of $55.6M beats by $2.
87M.
